These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 23770010)

  • 41. A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function.
    Hoogi S; Eisenberg V; Mayer S; Shamul A; Barliya T; Cohen CJ
    J Immunother Cancer; 2019 Sep; 7(1):243. PubMed ID: 31500665
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.
    Powell DJ; Dudley ME; Hogan KA; Wunderlich JR; Rosenberg SA
    J Immunol; 2006 Nov; 177(9):6527-39. PubMed ID: 17056585
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy.
    Wang LX; Kjaergaard J; Cohen PA; Shu S; Plautz GE
    J Immunol; 2004 Mar; 172(6):3462-8. PubMed ID: 15004146
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid.
    Parente-Pereira AC; Shmeeda H; Whilding LM; Zambirinis CP; Foster J; van der Stegen SJ; Beatson R; Zabinski T; Brewig N; Sosabowski JK; Mather S; Ghaem-Maghami S; Gabizon A; Maher J
    J Immunol; 2014 Dec; 193(11):5557-66. PubMed ID: 25339667
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.
    Wallen H; Thompson JA; Reilly JZ; Rodmyre RM; Cao J; Yee C
    PLoS One; 2009; 4(3):e4749. PubMed ID: 19270751
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.
    Yee C; Thompson JA; Byrd D; Riddell SR; Roche P; Celis E; Greenberg PD
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16168-73. PubMed ID: 12427970
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting dendritic cells with antigen-containing liposomes: antitumour immunity.
    Altin JG; van Broekhoven CL; Parish CR
    Expert Opin Biol Ther; 2004 Nov; 4(11):1735-47. PubMed ID: 15500402
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
    Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
    Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.
    Wittling MC; Knochelmann HM; Wyatt MM; Rangel Rivera GO; Cole AC; Lesinski GB; Paulos CM
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38945552
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice.
    Chinnasamy D; Yu Z; Kerkar SP; Zhang L; Morgan RA; Restifo NP; Rosenberg SA
    Clin Cancer Res; 2012 Mar; 18(6):1672-83. PubMed ID: 22291136
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.
    Dhupkar P; Gordon N
    Adv Exp Med Biol; 2017; 995():33-51. PubMed ID: 28321811
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
    Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
    J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L.
    Díaz-Montero CM; Zidan AA; Pallin MF; Anagnostopoulos V; Salem ML; Wieder E; Komanduri K; Montero AJ; Lichtenheld MG
    Immunol Res; 2013 Dec; 57(1-3):23-33. PubMed ID: 24218360
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impaired T cell proliferation by
    Chee J; Wilson C; Buzzai A; Wylie B; Forbes CA; Booth M; Principe N; Foley B; Cruickshank MN; Waithman J
    Epigenetics; 2020; 15(1-2):134-144. PubMed ID: 31423932
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Membrane-attached Cytokines Expressed by mRNA Electroporation Act as Potent T-Cell Adjuvants.
    Weinstein-Marom H; Pato A; Levin N; Susid K; Itzhaki O; Besser MJ; Peretz T; Margalit A; Lotem M; Gross G
    J Immunother; 2016; 39(2):60-70. PubMed ID: 26849075
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Clin Immunol Immunopathol; 1994 Oct; 73(1):115-22. PubMed ID: 7923908
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.
    Lou Y; Wang G; Lizée G; Kim GJ; Finkelstein SE; Feng C; Restifo NP; Hwu P
    Cancer Res; 2004 Sep; 64(18):6783-90. PubMed ID: 15374997
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene.
    Chang AE; Sondak VK; Bishop DK; Nickoloff BJ; Mulligan RC; Mulé JJ
    Hum Gene Ther; 1996 Apr; 7(6):773-92. PubMed ID: 9053030
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.